In fall 2024, xanomeline trospium chloride (XT) was approved by the U.S. Food and Drug Administration for the treatment of adults with schizophrenia. In an earlier post, we reviewed evidence that this ...
An association between oral microbiota and cognitive performance in schizophrenia has been reported by researchers at Science Tokyo. By analyzing saliva samples and cognitive test scores from patients ...
A new study reveals that COVID-19 patients suffer from significant, long-term cognitive deficits even a year after hospitalization, with brain injury markers and reduced brain volume suggesting immune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results